tirzepatide systematic review vs. Semaglutide for Patients with Obesity: A Head-to-Head Trial https://jwat.ch/3ZijGUc Adverse events associated with tirzepatide:

Di Prospero NA, Yee J, Frustaci ME, Samtani MN, Alba M, Fleck P

We offer a quick 5-minute health assessment quiz to help determine if youre a candidate for Hormone Replacement Therapy

Combining semaglutide and lipotropic injections can offer multiple benefits for weight loss

Tosin, is a triple board-certified internal medicine, obesity medicine, and lifestyle medicine physician and a Fellow of the American College of Physicians, with over twenty years of clinical experience

The results follow previous research* from the same international team finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such as heart attacks and strokes for people with obesity or who were overweight and had cardiovascular disease

22, 2025, and previous reporting by The Associated Press